Significantly, unlike the Mnk inhibitors (CGP57380 and cercosporamide) and two clinically relevant retinoids (ATRA and 4-HPR) [35, 36], RRs show potent breast cancer cell growth inhibition and down-regulation of p-eIF4E. This evidence concerns the gene ATP7A and breast carcinoma.